Nu Skin Enterprises, Inc.
NYSE:NUSHousehold & Personal Products
+$0.13 today
- Market cap
- $188.38M
- Beta
- 0.95
- P/E (TTM)
- 4.5
- EPS (TTM)
- $1.13
- Dividend yield
- 4.70%
Volume 0.59M
Average 0.57M
NUS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Nu Skin Enterprises, Inc.NYSE: NUS
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $3.7M fell 60.3% year over year, behind the -7.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 16.9% from the prior quarter. Over 3 fiscal years it compounded at +24.9% a year.
Context
- Stock-based compensation amounted to 1.6% of revenue in FY2025, up 0.8 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -60.3% toward the trailing-twelve-month pace of -7.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 24.11M USD
- Year-over-year change
- +62.6%
- 4-year CAGR
- +1.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.11M | +62.6% |
| FY2024 | 2024-12-31 | 14.82M | -5.3% |
| FY2023 | 2023-12-31 | 15.65M | +26.5% |
| FY2022 | 2022-12-31 | 12.37M | -46.7% |
| FY2021 | 2021-12-31 | 23.19M | — |
Stock-Based Compensation vs competitors
How NUS compares with its peers on the latest reported figures
- NUS's LTM Mar 2026 stock-based compensation of $18.49M is the 2nd largest of the 8 companies compared; the peer median is $5.73M.
- Its year-over-year change of -7.0% is the 5th highest of 7, against a peer median of +12.5%.
- Stock-based compensation amounts to 1.3% of revenue for NUS, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $31.66M | +33.6% | -2.9% | 11.9% | |
| LTM Mar 2026 | $18.49M | -7.0% | +24.9% | 1.3% | |
| LTM Mar 2026 | $12.54M | -14.0% | -28.0% | 1.4% | |
| LTM Mar 2026 | $8.42M | +5.0% | +1.4% | 1.3% | |
| LTM Mar 2026 | $5.73M | +19.9% | +20.8% | 1.1% | |
| LTM Mar 2026 | $4.64M | +27.3% | -5.1% | 0.9% | |
| LTM Apr 2026 | $2.78M | -25.2% | +14.0% | 0.1% | |
| LTM Dec 2025 | $0 | — | — | — | |
| Peer median (excluding NUS) | $5.73M | +12.5% | -0.7% | 1.2% | |
Competitors are the stored peer set for NUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 147.27M | 104.78M | 8.6M | (146.59M) | 160.2M |
| Depreciation & Amortization | 76.32M | 72.51M | 70.92M | 69.81M | 52.26M |
| Deferred Income Tax | 5.82M | (51.63M) | (18.09M) | (55.48M) | 20K |
| Stock-Based Compensation | 23.19M | 12.37M | 15.65M | 14.82M | 24.11M |
| Change in Working Capital | (193.62M) | (92.68M) | (81.68M) | (28.34M) | (69.62M) |
| Accounts Receivables | 20.22M | (11.45M) | (22.68M) | (7.76M) | 10.06M |
| Inventory | (95.32M) | 40.31M | (13.22M) | 30.32M | 11.89M |
| Accounts Payables | (13.28M) | 9.26M | (10.08M) | (7.29M) | (9.11M) |
| Other Working Capital | (105.24M) | (130.8M) | (35.7M) | (43.6M) | (82.45M) |
| Other Non-Cash Items | 82.6M | 62.71M | 123.25M | 257.52M | (86.69M) |
| Operating Cash Flow | 141.58M | 108.06M | 118.64M | 111.74M | 80.29M |
| Capital Expenditures | (68.62M) | (59.06M) | (58.49M) | (41.58M) | (34.28M) |
| Acquisitions (Net) | (18.96M) | 8.02M | (77.28M) | 0 | 0 |
| Purchases of Investments | (16.24M) | (13.96M) | (16.88M) | (14.76M) | 0 |
| Sales of Investments | 15.09M | 5.93M | 18.15M | 18.38M | 10.21M |
| Other Investing Activities | 0 | (8.02M) | 0 | 0 | 194.73M |
| Investing Cash Flow | (88.73M) | (67.08M) | (134.5M) | (37.96M) | 170.66M |
| Debt Repayment | 38.13M | 25.58M | 100M | (112.89M) | (170M) |
| Common Stock Issued | 0 | 0 | 4.56M | 0 | (1.91M) |
| Common Stock Repurchased | (80.42M) | (70.05M) | (13.01M) | (2.06M) | (20.04M) |
| Dividends Paid | (76.27M) | (77.02M) | (77.62M) | (11.93M) | (11.83M) |
| Other Financing Activities | 13.86M | 21.98M | (3.2M) | (6.3M) | 1.38M |
| Financing Cash Flow | (104.7M) | (99.5M) | 10.73M | (133.18M) | (202.4M) |
| Effect of Forex Changes | (11.24M) | (16.35M) | (3.54M) | (9.78M) | 3.2M |
| Net Change in Cash | (63.09M) | (74.87M) | (8.67M) | (69.17M) | 51.75M |
| Free Cash Flow | 72.97M | 49.01M | 60.15M | 70.16M | 46.01M |
Nu Skin Enterprises, Inc.
NYSE:NUS
Intrinsic Alpha fair value
Locked
Current Price
$3.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.